Hereditary pancreatitis amlodipine trial: A pilot study of a calcium-channel blocker in hereditary pancreatitis

Pancreas

Volumn 35, Issue 4, 2007, Pages 308-312

  Morinville, Véronique D ^a,b   Lowe, Mark E ^c   Elinoff, Beth D ^a   Whitcomb, David C ^a,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Amlodipine; Hereditary pancreatitis; Management; Pain; Safety

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; CALCIUM CHANNEL BLOCKING AGENT; PRSS1 PROTEIN; TRYPSINOGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE MUTATION; HEALTH SURVEY; HUMAN; INFORMED CONSENT; LABORATORY TEST; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PANCREATITIS; PARESTHESIA; PHYSICAL EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AMLODIPINE; ANALGESICS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHILD; FEASIBILITY STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PAIN; PAIN MEASUREMENT; PANCREATITIS; PATIENT DROPOUTS; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRYPSINOGEN;

EID: 37349025745     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e318120023a     Document Type: Article

References (36)

1. Comfort M, Steinberg A. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology. 1952;21:54-63.
2. Sossenheimer MJ, Aston CE, Preston RA, et al. Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSG). Am J Gastroenterol. 1997;92:1113-1116.
3. Whitcomb DC. Hereditary, familial and genetic disorders of the pancreas and pancreatic disorders in childhood. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th ed. Philadelphia: WB Saunders Co; 2006:1203-1240.
4. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252-261.
5. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141-145.
6. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997;113:1063-1068.
7. Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999;117:7-10.
8. Pfützer R, Myers E, Applebaum-Shapiro S, et al. Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002;50:271-272.
9. Simon P, Weiss FU, Sahin-Tóth M, et al. Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 - > Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem. 2001;21:21.
10. Whitcomb DC. Value of genetic testing in management of pancreatitis. Gut. 2004;53:1710-1717.
11. 2+ to trypsinogen and its relation to the mechanism of activation. Biochem Biophys Res Commun. 1967;28:390-394.
12. Bode W, Schwager P. The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J Mol Biol. 1975;98:693-717.
13. Colomb E, Guy O, Deprez P, et al. The two human trypsinogens: catalytic properties of the corresponding trypsins. Biochem Biophys Acta. 1978;525:186-193.
14. Frick TW, Fernandez del CC, Bimmler D, et al. Elevated calcium and activation of trypsinogen in rat pancreatic acini. Gut. 1997;41:339-343.
15. Kruger B, Albrecht E, Lerch MM. The role of intracellular calcium signaling in premature protease activation and the onset of pancreatitis. Am J Pathol. 2000;157:43-50.
16. Sutton R, Criddle D, Raraty MG, et al. Signal transduction, calcium and acute pancreatitis. Pancreatology. 2003;3:497-505.
17. Raraty M, Ward J, Erdemli G, et al. Calcium-dependent enzyme activation and vacuole formation in the apical granular region of pancreatic acinar cells. Proc Natl Acad Sci U S A. 2000;97:13126-13131.
18. Criddle DN, Murphy J, Fistetto G, et al. Fatty acid ethyl esters cause pancreatic calcium toxicity via inositol trisphosphate receptors and loss of ATP synthesis. Gastroenterology. 2006;130:781-793.
19. 2+ entry and exit pathways in exocrine gland cells. Cell Calcium. 2003;33:337-344.
20. 2+ signalling and pancreatitis: effects of alcohol, bile and coffee. Trends Pharmacol Sci. 2006;27:113-120.
21. 2+ influx mechanism. J Biol Chem. 1987;262:16963-16968.
22. 2+ entry through basal membrane patch. Cell. 1997;88:49-55.
23. Putney JW Jr. A model for receptor-regulated calcium entry. Cell Calcium. 1986;7:1-12.
24. Krause E, Pfeiffer F, Schmid A, et al. Depletion of intracellular calcium stores activates a calcium conducting nonselective cation current in mouse pancreatic acinar cells. J Biol Chem. 1996;271:32523-32528.
25. Slomka M, Celinski K, Wargocki J, et al. The influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on the development of experimental acute pancreatitis. Ann Univ Mariae Curie Sklodowska [Med]. 2001;56:29-34.
26. Zhou W, Shen F, Miller JE, et al. Evidence for altered cellular calcium in the pathogenetic mechanism of acute pancreatitis in rats. J Surg Res. 1996;60:147-155.
27. Hughes CB, el-Din AB, Kotb M, et al. Calcium channel blockade inhibits release of TNF alpha and improves survival in a rat model of acute pancreatitis. Pancreas. 1996;13:22-28.
28. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc. 2002;56:202-208.
29. Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353-359.
30. Deng X, Guarita DR, Pedroso MR, et al. Area postrema lesion alters the effects of peptide YY on 2-DG-stimulated pancreatic exocrine secretion. Dig Dis Sci. 2001;46:2460-2469.
31. 2+ channel currents in differentiated PC12 cells. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:335-342.
32. 2+ channels by amlodipine. Br J Pharmacol. 1997;121:1136-1140.
33. Furukawa T, Yamakawa T, Midera T, et al. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999;291:464-473.
34. 2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001;419:175-181.
35. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;2:662-670.
36. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today. 2006;11:245-253.